Prednisolone exerts exquisite inhibitory properties on platelet functions
Elisabetta Liverani, Sreemoti Banerjee, Wayne Roberts, Khalid M Naseem, Mauro Perretti, Elisabetta Liverani, Sreemoti Banerjee, Wayne Roberts, Khalid M Naseem, Mauro Perretti
Abstract
We have previously reported presence of the glucocorticoid (GC) receptor (GR) alpha on blood platelets, and its ability to modulate platelet aggregation when activated by the synthetic GC prednisolone (Pred). In the present study we investigated the effects of Pred on broader aspects of platelet functions to unveil novel non-genomic actions on this cell type. Using whole blood assay we demonstrated that Pred was the only GC able to inhibit platelet aggregation and platelet-monocyte interactions. This latter effect was due to regulation of platelets, not monocytes. We next examined the effects of Pred on physiological actions of platelets, observing inhibition of platelet adhesion and spreading on collagen under static conditions. Moreover Pred inhibited thrombus formation under flow, suggesting potential important effects in haemostasis and thrombosis. Pred was unable to regulate platelet reactivity under conditions where the effects of platelet-derived ADP and TxA₂ were blocked, suggesting that the GC targeted the activation-dependent component of the adhesion and aggregation response. The effects of Pred were not mediated through cyclic nucleotide signaling, but rather seemed to evolve around selective regulation of P2Y₁₂ ADP receptor signaling, intimating a novel mode of action. This study details the actions of Pred on platelets unveiling novel properties which could be relevant for this GC in controlling unwanted vascular and thrombotic diseases.
Copyright © 2012 Elsevier Inc. All rights reserved.
Figures
References
- Adcock I.M. Molecular mechanisms of glucocorticosteroid actions. Pulm Pharmacol Ther. 2000;13:115–126.
- Liberman A.C., Druker J., Garcia F.A., Holsboer F., Arzt E. Intracellular molecular signaling basis for specificity to glucocorticoid anti-inflammatory actions. Ann N Y Acad Sci. 2009;1153:6–13.
- Buttgereit F., Scheffold A. Rapid glucocorticoid effects on immune cells. Steroids. 2002;67:529–534.
- Schulz M., Schneider S., Lottspeich F., Renkawitz R., Eggert M. Identification of nucleolin as a glucocorticoid receptor interacting protein. Biochem Biophys Res Commun. 2001;280:476–480.
- Lowenberg M., Verhaar A.P., van den Brink G.R., Hommes D.W. Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression. Trends Mol Med. 2007;13:158–163.
- Bartholome B., Spies C.M., Gaber T., Schuchmann S., Berki T., Kunkel D. Membrane glucocorticoid receptors (mGCR) are expressed in normal human peripheral blood mononuclear cells and up-regulated after in vitro stimulation and in patients with rheumatoid arthritis. Faseb J. 2004;18:70–80.
- Lowenberg M., Verhaar A.P., Bilderbeek J., Marle J., Buttgereit F., Peppelenbosch M.P. Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated protein complex containing LCK and FYN. EMBO Rep. 2006;7:1023–1029.
- Lowenberg M., Tuynman J., Bilderbeek J., Gaber T., Buttgereit F., van Deventer S. Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn. Blood. 2005;106:1703–1710.
- Yazid S., Leoni G., Getting S.J., Cooper D., Solito E., Perretti M. Antiallergic cromones inhibit neutrophil recruitment onto vascular endothelium via annexin-A1 mobilization. Arterioscler Thromb Vasc Biol. 2010;30:1718–1724.
- Bishop-Bailey D. The platelet as a model system for the acute actions of nuclear receptors. Steroids. 2010;75:570–575.
- Moraes L.A., Paul-Clark M.J., Rickman A., Flower R.J., Goulding N.J., Perretti M. Ligand-specific glucocorticoid receptor activation in human platelets. Blood. 2005;106:4167–4175.
- Schafer A., Bauersachs J. Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis. Curr Vasc Pharmacol. 2008;6:52–60.
- Roberts W., Riba R., Homer-Vanniasinkam S., Farndale R.W., Naseem K.M. Nitric oxide specifically inhibits integrin-mediated platelet adhesion and spreading on collagen. J Thromb Haemost. 2008;6:2175–2185.
- Roberts W., Michno A., Aburima A., Naseem K.M. Nitric oxide inhibits von Willebrand factor-mediated platelet adhesion and spreading through regulation of integrin alpha(IIb)beta(3) and myosin light chain. J Thromb Haemost. 2009;7:2106–2115.
- Shattil S.J., Kashiwagi H., Pampori N. Integrin signaling: the platelet paradigm. Blood. 1998;91:2645–2657.
- Davi G., Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482–2494.
- Garnotel R., Wegrowski J., Bellon G., Monboisse J.C., Perreau C., Borel J.P. Adhesion and activation of human neutrophils onto collagen chains separated by electrophoresis. Exp Cell Res. 1993;205:426–429.
- Siller-Matula J.M., Christ G., Lang I.M., Delle-Karth G., Huber K., Jilma B. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. J Thromb Haemost. 2010;8:351–359.
- Rupprecht R., Reul J.M., van Steensel B., Spengler D., Soder M., Berning B. Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur J Pharmacol. 1993;247:145–154.
- Grossmann C., Scholz T., Rochel M., Bumke-Vogt C., Oelkers W., Pfeiffer A.F. Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol. 2004;151:397–406.
- Igarashi Y. [Synthetic mineralocorticoid, clinical application of fludrocortisone acetate (Florinef)] Nippon Rinsho. 1994;52:779–786.
- Weyts F.A. Verburg-van Kemenade BM, Flik G. Characterisation of glucocorticoid receptors in peripheral blood leukocytes of Carp, Cyprinus carpio L. Gen Comp Endocrinol. 1998;111:1–8.
- Perretti M., Paul-Clark M.J., Mancini L., Flower R.J. Generation of innovative anti-inflammatory and anti-arthritic glucocorticoid derivatives that release NO: the nitro-steroids. Dig Liver Dis. 2003;35(Suppl. 2):S41–S48.
- Miner J.N., Hong M.H., Negro-Vilar A. New and improved glucocorticoid receptor ligands. Expert Opin Investig Drugs. 2005;14:1527–1545.
- Gremmel T., Kopp C.W., Seidinger D., Giurgea G.A., Koppensteiner R., Steiner S. The formation of monocyte-platelet aggregates is independent of on-treatment residual agonists’-inducible platelet reactivity. Atherosclerosis. 2009;207:608–613.
- Michelson A.D., Barnard M.R., Krueger L.A., Valeri C.R., Furman M.I. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation. 2001;104:1533–1537.
- Braun O.O., Johnell M., Varenhorst C., James S., Brandt J.T., Jakubowski J.A. Greater reduction of platelet activation markers and platelet–monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease. Thromb Haemost. 2008;100:626–633.
- Watson S.P., Gibbins J. Collagen receptor signalling in platelets: extending the role of the ITAM. Immunol Today. 1998;19:260–264.
- Behnke O. Microtubules in disk-shaped blood cells. Int Rev Exp Pathol. 1970;9:1–92.
- Born G.V. Observations on the change in shape of blood platelets brought about by adenosine diphosphate. J Physiol. 1970;209:487–511.
Source: PubMed